Should I invest in IMU a 130 million market cap needing to raise another 10-20 million to survive currently in phase 1 and a significantly smaller market potential and no other science to de risk the mechanism of action in humans. Plus billions of shares on the register
Or
Should I invest into NYR a 33 million market cap in a 60 billion dollar unmet market with phase 1 completion 2-4 weeks away and CEO already in plans starting a phase 2 will have enough money to complete a quick phase 2a with CEO stating clearly a licensing agreement for cardiovascular indication will be targeted after phase 2a plus AGN CEO already admitting they will combine with NYR in treating brain injury and AGN de risking the main mechanism of action in humans which is currently a 110 million market cap on phase 1 and results are 1-2 months away moving it well north of a 200 million market cap.
I wonder which has the bigger upside potential and which one is more de risked
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)